Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
NCT ID: NCT00318500
Last Updated: 2007-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
150 participants
INTERVENTIONAL
2006-05-31
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ERB-041
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sexually active, nonpregnant, nonlactating women (18-45 years) with regular menstrual cycles who are willing to use non-hormonal contraception
Exclusion Criteria
* Prophylactic use of analgesics to avoid endometriosis-related pain
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montgomery, Alabama, United States
Chandler, Arizona, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
San Francisco, California, United States
Vista, California, United States
Denver, Colorado, United States
Denver, Colorado, United States
New Britain, Connecticut, United States
Clearwater, Florida, United States
New Port Richey, Florida, United States
Plantation, Florida, United States
Venice, Florida, United States
West Palm Beach, Florida, United States
West Palm Beach, Florida, United States
Marietta, Georgia, United States
Idaho Falls, Idaho, United States
Oak Brook, Illinois, United States
Evansville, Indiana, United States
Reno, Nevada, United States
Lawrenceville, New Jersey, United States
Durham, North Carolina, United States
New Bern, North Carolina, United States
Raleigh, North Carolina, United States
Winston-Salem, North Carolina, United States
Cleveland, Ohio, United States
Miamisburg, Ohio, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
Abington, Pennsylvania, United States
Lansdale, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Columbia, South Carolina, United States
Greenville, South Carolina, United States
Bristol, Tennessee, United States
Chattanooga, Tennessee, United States
Memphis, Tennessee, United States
Corpus Christi, Texas, United States
San Antonio, Texas, United States
West Valley City, Utah, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
Renton, Washington, United States
Madison, Wisconsin, United States
Randwick, New South Wales, Australia
Sydney, New South Wales, Australia
Richmond, Victoria, Australia
Nedlands, Western Australia, Australia
Herestraat, Leuven, Belgium
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Saskatoon, Saskatchewan, Canada
Hong Kong, , Hong Kong
Cape Town, Capetown, South Africa
Port Elizabeth, Eastern Cape, South Africa
Roodepoort, Jgb Gauteng, South Africa
Durban, KwaZulu-Natal, South Africa
Nottingham, Nottinghamshire, United Kingdom
Glasgow, Scotland, United Kingdom
Sheffield, South Yorshire, United Kingdom
Swindon, Wiltshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3142A2-203
Identifier Type: -
Identifier Source: org_study_id